Patents and Proprietary Position
LINC’s technology for the PTHrP-based diagnosis and treatment of
fibrotic disorders of the lung and other major organs is protected by filed
patent applications, as well as trade secrets which cover details of the
discovery not outlined in the patents. International patents have also
been filed on LINC’s core technology. Numerous patents in the
pulmonay field have also been evaluated to gauge the “freedom to
practice”. Although the technology appears to be unencumbered,
additional evaluations will be needed from qualified patent attorneys.
A US patent on the “Use of Parathyroid Hormone-Related Protein
(PTHRP) in the Diagnosis and Treatment of Chronic Lung Disease and
Other Pathologies” was filed October 25, 2002 by Drs. Torday and
Rehan. The patent is assigned to the Research and Education Institute at
Harbor/UCLA (REI), and the exclusive world-wide rights to the
technology has been obtained by LINC. This technology covers the use
of PTHrP and its down-stream modulators in the diagnosis and treatment
of fibrotic lung disease and other pathologies.
|
